Bhaskar Dasgupta Selected Research

Therapeutics

11/2023	Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
10/2023	Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
5/2021	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
1/2021	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
1/2020	2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
9/2018	Current and emerging therapies in large-vessel vasculitis.
3/2017	A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy.
8/2016	Emerging therapies in large vessel vasculitis.
1/2016	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.
10/2015	2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bhaskar Dasgupta Research Topics

Disease

29	Giant Cell Arteritis (Horton Disease) 10/2023 - 09/2007
10	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 10/2023 - 08/2010
8	Rheumatoid Arthritis 11/2023 - 04/2008
5	Rheumatic Diseases (Rheumatism) 11/2023 - 08/2014
5	Vasculitis (Vasculitides) 01/2023 - 01/2016
5	Pain (Aches) 01/2016 - 06/2007
4	Necrosis 01/2021 - 08/2014
3	Fatigue 01/2018 - 01/2016
3	Shoulder Pain 04/2012 - 03/2011
2	Arthralgia (Joint Pain) 10/2023 - 04/2012
2	Inflammation (Inflammations) 08/2023 - 07/2023
2	Acute-Phase Reaction 01/2020 - 06/2007
2	Infections 01/2018 - 01/2016
2	Hypertension (High Blood Pressure) 01/2018 - 11/2011
2	Osteoporosis 01/2018 - 01/2016
2	Diabetes Mellitus 01/2018 - 01/2016
2	Gout 09/2017 - 07/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2016 - 01/2015
1	Neutropenia 10/2023
1	Diarrhea 10/2023
1	Virus Diseases (Viral Diseases) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Hepatitis 01/2021
1	Takayasu Arteritis (Arteritis, Takayasu's) 01/2020
1	Osteonecrosis (Kienbock's Disease) 01/2018
1	Cataract (Cataracts) 01/2018
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2018
1	Chronic Renal Insufficiency 09/2017
1	Neurosarcoidosis 03/2017
1	Ischemic Optic Neuropathy (Anterior Ischemic Optic Neuropathy) 01/2017
1	Systemic Juvenile Rheumatoid Arthritis 01/2017
1	Arthritis (Polyarthritis) 01/2017
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2017
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2016
1	Weight Gain 10/2015
1	Disease Susceptibility (Diathesis) 04/2015
1	Aortic Aneurysm (Aneurysm, Aortic) 01/2015
1	Long Term Adverse Effects 01/2013
1	Atherosclerosis 11/2011
1	Headache (Headaches) 03/2011
1	Synovitis 03/2011
1	Granuloma 11/2010
1	Myositis (Idiopathic Inflammatory Myopathies) 10/2010
1	Muscular Diseases (Myopathy) 10/2010
1	Dermatomyositis (Dermatopolymyositis) 10/2010
1	Polymyositis 10/2010
1	Inclusion Body Myositis 10/2010

Drug/Important Bio-Agent (IBA)

13	tocilizumab (atlizumab)FDA Link 11/2023 - 01/2013
13	GlucocorticoidsIBA 10/2023 - 10/2015
9	Prednisone (Sone)FDA LinkGeneric 10/2023 - 01/2013
6	Interleukin-6 (Interleukin 6)IBA 10/2023 - 11/2010
6	C-Reactive ProteinIBA 10/2023 - 03/2011
6	SteroidsIBA 03/2020 - 06/2007
5	golimumab FDA Link 01/2016 - 04/2008
5	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2015 - 10/2008
4	Antirheumatic Agents (DMARD)IBA 11/2023 - 08/2014
4	Biomarkers (Surrogate Marker)IBA 11/2023 - 07/2009
3	CytokinesIBA 01/2021 - 11/2010
3	Monoclonal AntibodiesIBA 01/2017 - 07/2009
2	Rituximab (Mabthera)FDA Link 11/2023 - 01/2021
2	sarilumabIBA 10/2023 - 10/2023
2	Leflunomide (Arava)FDA LinkGeneric 01/2022 - 10/2021
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 11/2020
2	Prednisolone (Predate)FDA LinkGeneric 10/2019 - 01/2018
2	InterleukinsIBA 10/2019 - 01/2013
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 09/2017 - 07/2015
2	Methylprednisolone FDA LinkGeneric 09/2017 - 10/2015
2	interleukin-6 receptor alphaIBA 01/2017 - 01/2017
2	Amino Acids FDA Link 07/2015 - 04/2015
2	Creatine Kinase (Creatine Phosphokinase)IBA 10/2010 - 07/2007
2	Methotrexate (Mexate)FDA LinkGeneric 07/2009 - 04/2008
1	Etanercept (Enbrel)FDA Link 11/2023
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022
1	mavrilimumabIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	sirukumabIBA 12/2020
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2019
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 09/2017
1	Interleukin-1 (Interleukin 1)IBA 09/2017
1	Infliximab (Remicade)FDA Link 03/2017
1	Biosimilar PharmaceuticalsIBA 03/2017
1	PlasminogenIBA 01/2017
1	InterferonsIBA 01/2016
1	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2016
1	HLA-DRB1 Chains (HLA DRB1)IBA 07/2015
1	Antihypertensive Agents (Antihypertensives)IBA 01/2015
1	olokizumabIBA 09/2014
1	Tumor Necrosis Factor InhibitorsIBA 09/2014
1	SR-ATIBA 01/2013
1	Rheumatoid FactorIBA 04/2012
1	Anti-Citrullinated Protein AntibodiesIBA 04/2012
1	ORALIT (ORS)IBA 11/2011
1	Fibrinogen (Factor I)FDA Link 03/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2010
1	Troponin T (Troponin T1)IBA 10/2010
1	Interleukin-18 (Interleukin 18)IBA 07/2009

Therapy/Procedure

15	Therapeutics 11/2023 - 07/2009
2	Biological Therapy 11/2023 - 01/2021
1	Remission Induction 01/2020
1	Polypharmacy 01/2016